当前位置 : 首页 > 人才招聘

人才招聘

浙江大学转化医学研究院闵军霞教授团队 诚聘肿瘤靶向及免疫治疗研究方向博士后

编辑:admin 时间:2017年01月06日 访问次数:687

团队负责人闵军霞,美国University of Missouri-Columbia大学博士,教授,博士生导师,浙江省海外引进高层次浙江省千人创新学者。先后在美国哈佛大学医学院(博士后)及诺华制药Boston, Group Leader从事肿瘤转化医学研究并取得系列重大成果,论文发表在Nature Medicine》、《PNAS》、《Molecular Cancer Research》、《Cancer Research.等国际著名学术期刊。
团队以自主研发的新型生物信息驱动网络技术,结合基因敲除小鼠及肿瘤病人裸鼠模型等先进技术平台开展肿瘤转化医学研究。主要研究方向:1)肿瘤与生物大数据挖掘;2)中国高发消化道肿瘤的靶向治疗及免疫治疗新策略;3)金属代谢与肿瘤发生分子机制。
因课题发展需要,拟招聘博士后2名,工资待遇从优。基本条件如下:
1)在免疫学、肿瘤生物学、分子生物学、细胞生物学、肿瘤病理学等专业获得或即将获得国内外知名大学博士学位。免疫学及肿瘤生物学优先
2)热爱科学研究,在国际期刊发表研究性学术论文。
3)熟悉分子生物学实验技术,有较好的英文交流能力,较强独立科研能力。
请应聘者将个人简历以email形式发送至rdeyouxiang@qq.com, (邮件标题请注明博士后申请)。若初审通过,将在近期发出面试通知。申请材料将予以保密,招聘信息在职位满额前一直有效。
联系方式:靳善睿,Emailrdeyouxiang@qq.comqq3137415099
 
近年代表性论文
1.Min J., et al.  Molecular Cancer Research,2005,3:287-296.4
2.Van Driessche N, et al. PNAS. 2007 Sep 25;104(39):15406-11
3.Min J, et al. Molecular Cancer Research. 2007 Aug;5(8):801-12
4.Min J, et al. Nature Medicine. 2010 Mar;16(3):286-94
5.Jaeger S. et al. Journal of Biomolecular Screening. 2014 Feb 11
6.Fang X, et al. European Journal of Cancer. 2015 Dec;51(18):2820-32
7.Zhou Q et al Cancer Research. 2015 May 15;75(10):1949-58
8.Fang X, et al.BMC Med. 2016 Dec 8;14(1):210
9.Zeng Y, et al. Sci Rep. 2016 Feb 25; 6:21243
 
 

Postdoctoral Positions at Min Lab 

Institute of Translational Medicine, Zhejiang University

Cancer Translational Research at Zhejiang University has an exciting opportunity for a motivated postdoc scientist with an interest in novel cancer therapeutics in the laboratory of Dr. Junxia Min, located at the beautiful scenic city Hangzhou, China. Dr Min has been working in the United States for over a decade. She got her Ph.D from the University of Missouri-Columbia in 2006, and then worked as a postdoc at Harvard Medical School. Since 2010, Dr Min has been working at the Department of Oncology, Novartis as a group leader. In 2014, Dr Min was recruited as a full professor at Institute of Translational Medicine, Zhejiang University. A major focus of the Min Lab is to identify curative precision cancer therapeutics. Dr. Min’s research interest has been mainly focusing on 4 areas: 1. to explore novel cancer therapeutics, including molecular targeted therapy andimmunotherapy; 2. to elucidate molecular mechanisms of resistance to targeted cancer therapeutics; 3. to further refine the previously established causal network models for realizably predicting drug sensitivity and defining driving pathways in Asian-prevalent tumor types; 4. Interconnected cancer and aging. The work utilizes integrative patients’ omics data, cancer biology, genetically engineered mice in conjunction with patient-derived tumor xenografts, and cell biology to study driving genes/pathways involved in tumorigenesis.
The successful applicant must have, or be in the process of completing, a PhD. The ideal candidate will have immunology training background. All candidates must be highly motivated and have a strong record of independent research. Prior experience of work in each of these areas as well as experience with live animals and knowledge of bioengineering techniques is a plus. Please submit a letter of interest, along with your resume, copies of any relevant publications, and names/addresses of three possible references.
 
 
Contact:
Mr. Shanrui Jin
Institute of Translational Medicine
The First Affiliated Hospital
Zhejiang University
Yuhangtang Road 866#,
Hangzhou, Zhejiang Province, 310058 China
Phone
+86-17306432620
Email:
rdeyouxiang@qq.com